Phân tích chi tiết tính chất gây huyết khối và kết quả một năm ở bệnh nhân thực hiện cấy ghép WATCHMAN: (TARGET-WATCHMAN) một nghiên cứu trường hợp – đối chứng

Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr, Prevail IPA (2017) 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 70(24):2964–2975. https://doi.org/10.1016/j.jacc.2017.10.021 Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY (2014) Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64(1):1–12. https://doi.org/10.1016/j.jacc.2014.04.029 Belgaid DR, Khan Z, Zaidi M, Hobbs A (2016) Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. Int J Cardiol 219:177–179. https://doi.org/10.1016/j.ijcard.2016.06.041 Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D, Investigators PA (2013) Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation 127(6):720–729. https://doi.org/10.1161/CIRCULATIONAHA.112.114389 Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Mazzone P, Foley D, Grygier M, Sievert H, De Potter T, Vireca E, Stein K, Bergmann MW, following i, institutions participated in the Es (2019) Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology. Circ Arrhythm Electrophysiol 12(4):e006841. https://doi.org/10.1161/CIRCEP.118.006841 Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H (2013) Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with Watchman left atrial appendage closure technology). J Am Coll Cardiol 61(25):2551–2556. https://doi.org/10.1016/j.jacc.2013.03.035 Price MJ, Reddy VY, Valderrabano M, Halperin JL, Gibson DN, Gordon N, Huber KC, Holmes DR Jr (2015) Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. JACC Cardiovasc Interv 8(15):1925–1932. https://doi.org/10.1016/j.jcin.2015.08.035 Holmes DR Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy VY (2015) Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65(24):2614–2623. https://doi.org/10.1016/j.jacc.2015.04.025 Holmes DR, Reddy VY, Buchbinder M, Stein K, Elletson M, Bergmann MW, Schmidt B, Saw J (2017) The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am Heart J 189:68–74. https://doi.org/10.1016/j.ahj.2017.03.007 Romero J, Briceno DF, Di Biase L (2019) NOACs versus VKAs during Watchman implantation in patients with atrial fibrillation: the end of an era. Pacing Clin Electrophysiol 42(10):1310–1311. https://doi.org/10.1111/pace.13797 Gurbel PA, Bliden KP, Tantry US, Monroe AL, Muresan AA, Brunner NE, Lopez-Espina CG, Delmenico PR, Cohen E, Raviv G, Haugen DL, Ereth MH (2016) First report of the point-of-care TEG: a technical validation study of the TEG-6S system. Platelets 27(7):642–649. https://doi.org/10.3109/09537104.2016.1153617 Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23):2908–2913. https://doi.org/10.1161/01.CIR.0000072771.11429.83 Bliden KP, Singla A, Gesheff MG, Toth PP, Tabrizchi A, Ens G, Guyer K, Singh M, Franzese CJ, Stapleton D, Tantry US, Gurbel PA (2014) Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. Thromb Haemost 112(2):323–331. https://doi.org/10.1160/TH14-01-0094 Milos M, Herak D, Kuric L, Horvat I, Zadro R (2009) Evaluation and performance characteristics of the coagulation system: ACL TOP analyzer—HemosIL reagents. Int J Lab Hematol 31(1):26–35. https://doi.org/10.1111/j.1751-553x.2007.00999.x Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49(6):657–666. https://doi.org/10.1016/j.jacc.2006.10.050 Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, Richardt G, Schulz S, Laugwitz KL, Massberg S, Schomig A, Kastrati A (2012) Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125(11):1424–1431. https://doi.org/10.1161/CIRCULATIONAHA.111.060871 Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN, Maini B, Gordon NT, Main ML, Reddy VY (2018) Device-related thrombus after left atrial appendage closure. Circulation 138(9):874–885. https://doi.org/10.1161/CIRCULATIONAHA.118.035090 Pracon R, Bangalore S, Dzielinska Z, Konka M, Kepka C, Kruk M, Kaczmarska-Dyrda E, Petryka-Mazurkiewicz J, Bujak S, Solecki M, Pskit A, Dabrowska A, Sieradzki B, Plonski A, Ruzyllo W, Witkowski A, Demkow M (2018) Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy. Circ Cardiovasc Interv 11(3):e005997. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005997 Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, Fatemi M, Franceschi F, Guedeney P, Jacon P, Paziaud O, Venier S, Deharo JC, Gras D, Klug D, Mansourati J, Montalescot G, Piot O, Defaye P (2018) Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol 71(14):1528–1536. https://doi.org/10.1016/j.jacc.2018.01.076 Lempereur M, Aminian A, Freixa X, Gafoor S, Kefer J, Tzikas A, Legrand V, Saw J (2017) Device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv 90(5):E111–E121. https://doi.org/10.1002/ccd.26903 Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46(10):1820–1826. https://doi.org/10.1016/j.jacc.2005.07.041 Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD, Investigators A-D (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614–623. https://doi.org/10.1016/S0140-6736(13)61170-8 Meus R, Son M, Sobczyk D, Undas A (2016) Prothrombotic state in patients with a left atrial appendage thrombus of unknown origin and cerebrovascular events. Stroke 47(7):1872–1878. https://doi.org/10.1161/STROKEAHA.116.012856 Johnson ED, Schell JC, Rodgers GM (2019) The d-dimer assay. Am J Hematol 94(7):833–839. https://doi.org/10.1002/ajh.25482 Bliden KP, Chaudhary R, Navarese EP, Sharma T, Kaza H, Tantry US, Gurbel PA (2018) Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: the MAGMA-ischemia score. Atherosclerosis 268:55–62. https://doi.org/10.1016/j.atherosclerosis.2017.11.018 Bliden KP, Raviv G, Tantry US, Chaudhary R, Cochran JW, Navarese EP, Brannan T, Vyas A, Gurbel PA (2019) "Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. J Thromb Thrombolysis 47(2):192–199. https://doi.org/10.1007/s11239-019-01813-0 Aradi D, Gross L, Trenk D, Geisler T, Merkely B, Kiss RG, Komocsi A, Dezsi CA, Ruzsa Z, Ungi I, Rizas KD, May AE, Mugge A, Zeiher AM, Holdt L, Huber K, Neumann FJ, Koltowski L, Huczek Z, Hadamitzky M, Massberg S, Sibbing D (2019) Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. Eur Heart J 40(24):1942–1951. https://doi.org/10.1093/eurheartj/ehz202 Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US (2007) Evaluation of dose-related effects ofaspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25):3156–3164. Olson JD (2015) D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem 69:1–46. Shahidi M (2017) Thrombosis and von Willebrand factor. Adv Exp Med Biol 906:285–306. Kattula S, Byrnes JR, Wolberg AS (2017) Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 37(3):e13–e21. Undas A (2017) Determination of fibrinogen and thrombin time (TT). Methods Mol Biol 1646:105–110.